Physician profile
Samuel Coleman
NPI 1386801280
$5,008.21
in general payments reported to CMS, 2019-2025
39 companies · $635 in 2025
The $635 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $332 · 2021: $994 · 2022: $643 · 2023: $916 · 2024: $664 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,214.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $562.29 | 2019-2025 | Repatha |
| Pfizer INC. | $544.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $448.35 | 2019-2025 | Brilinta, Wainua, Lokelma |
| Novartis Pharmaceuticals Corporation | $442.39 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $440.22 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.95 | 2019-2025 | Jardiance |
| Edwards Lifesciences Corporation | $277.84 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $220.59 | 2021-2025 | Verquvo |
| Daiichi Sankyo INC. | $181.03 | 2019-2025 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $167.07 | 2019-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $134.72 | 2019-2022 | |
| Abbott Laboratories | $132.69 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $106.05 | 2019-2023 | |
| Esperion Therapeutics, INC. | $93.05 | 2021-2025 | Nexletol |
| Atricure, INC. | $87.27 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.